drugset
drugset / Trial / NCT04169074

Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

NCT04169074 ↗

Phase 2 Terminated 7 enrolled University of Arizona George Washington University · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2021-07-07
Primary completion
2024-12-16
Completion
2025-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 200 mg Oral

Indications

head and neck squamous cell carcinoma